About
Risorius Co., Ltd. is a deep learning-based neurotechnology company advancing the quantification and personalization of care in psychiatry and neurology. We develop clinically actionable, EEG-based predictive biomarkers that support neuropsychiatric diagnosis, prognosis stratification, and precision drug prescription for both clinical practice and pharmaceutical development.
Leveraging proprietary EEG preprocessing models and end-to-end analysis pipelines powered by deep learning and explainable AI (xAI), Risorius transforms complex brain signals into interpretable insights that align with real-world clinical decision-making. Our platform is designed for scalability and multimodal expansion, with ongoing integration of MRI, polysomnography (PSG), and electronic health record (EHR) data to enable comprehensive brain-state characterization across disorders and treatment stages.
By bridging neuroscience, artificial intelligence, and clinical psychiatry, Risorius aims to redefine how brain data is quantified, interpreted, and applied—accelerating the transition toward objective, personalized neuropsychiatric care.